Involvement of mitochondrial aggregation in arsenic trioxide (As2O3)-induced apoptosis in human glioblastoma cells

Cancer Science

Volumn 96, Issue 11, 2005, Pages 825-833

  Haga, Naomi ^a   Fujita, Naoya ^a   Tsuruo, Takashi ^a,b  

^a UNIVERSITY OF TOKYO   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; CASPASE; PROTEIN BAX; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL AGGREGATION; CELL CULTURE; CELL DIFFERENTIATION; CELL MEMBRANE POTENTIAL; CELL PROLIFERATION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVATION; GLIOBLASTOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; MORPHOLOGY; OLIGOMERIZATION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BCL-2-ASSOCIATED X PROTEIN; BRAIN NEOPLASMS; CASPASES; ENZYME ACTIVATION; GLIOBLASTOMA; HUMANS; MEMBRANE POTENTIALS; MITOCHONDRIA; OXIDES; REACTIVE OXYGEN SPECIES; TUMOR CELLS, CULTURED;

EID: 29644436194     PISSN: 13479032     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2005.00114.x     Document Type: Article

References (61)

1. Berger F, Gay E, Pelletier L, Tropel P, Wion D. Development of gliomas: Potential role of asymmetrical cell division of neural stem cells. Lancet Oncol 2004; 5: 511-4.
2. Carpentier AF. Neuro-oncology: The growing role of chemotherapy in glioma. Lancet Neurol 2005; 4: 4-5.
3. Lefranc F, Brotchi J, Kiss R. Possible future issues in the treatment of glioblastomas: Special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol 2005; 23: 2411-22.
4. Alonso M, Tamasdan C, Miller DC, Newcomb EW. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Mol Cancer Ther 2003; 2: 139-50.
5. 3 exerts dose-dependent dual effects on APL cells. Blood 1997; 89: 3345-53.
6. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 1996; 88: 1052-61.
7. Kroemer G, de The H. Arsenic trioxide, a novel mitochondriotoxic anticancer agent? J Natl Cancer Inst 1999; 91: 743-5.
8. 3) in the treatment of acute promyelocytic, leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-60.
9. Soignet SL, Maslak P, Wang ZG et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-8.
10. Castaigne S, Chomienne C, Daniel MT et al. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990; 76: 1704-9.
11. Chen ZX, Xue YQ, Zhang R et al. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991; 78: 1413-9.
12. Huang ME, Ye YC, Chen SR et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567-72.
13. Warrell RP Jr, Frankel SR, Miller WH Jr et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991; 324: 1385-93.
14. Muindi J, Frankel SR, Miller WH Jr et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: Implications for relapse and retinoid 'resistance' in patients with acute promyelocytic leukemia. Blood 1992; 79: 299-303.
15. Robertson KA, Emami B, Collins SJ. Retinoic acid-resistant HL-60R cells harbor a point mutation in the retinoic acid receptor ligand-binding domain that confers dominant negative activity. Blood 1992; 80: 1885-9.
16. Zhu XH, Shen YL, Jing YK et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999; 91: 772-8.
17. Mahieux R, Pise-Masison C, Gessain A et al. Arsenic trioxide induces apoptosis in human T-cell leukemia virus type 1- and type 2-infected cells by a caspase-3-dependent mechanism involving Bcl-2 cleavage. Blood 2001; 98: 3762-9.
18. Kajiguchi T, Yamamoto K, Hossain K et al. Sustained activation of c-jun-terminal kinase (JNK) is closely related to arsenic trioxide-induced apoptosis in an acute myeloid leukemia (M2)-derived cell line, NKM-1. Leukemia 2003; 17: 2189-95.
19. Akao Y, Nakagawa Y, Akiyama K. Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro. FEBS Lett 1999; 455: 59-62.
20. Baumgartner M, Sturlan S, Roth E, Wessner B, Bachleitner-Hofmann T. Enhancement of arsenic trioxide-mediated apoptosis using docosahexaenoic acid in arsenic trioxide-resistant solid tumor cells. Int J Cancer 2004; 112: 707-12.
21. Hyun Park W, Hee Cho Y, Won Jung C et al. Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun 2003; 300: 230-5.
22. Kanzawa T, Kondo Y, Ito H, Kondo S, Germano I. Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res 2003; 63: 2103-8.
23. Lebedeva IV, Su ZZ, Sarkar D et al. Melanoma differentiation associated gene-7, mda-7/interleukin-24, induces apoptosis in prostate cancer cells by promoting mitochondrial dysfunction and inducing reactive oxygen species. Cancer Res 2003; 63: 8138-44.
24. 3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 2001; 61: 5432-40.
25. Seol JG, Park WH, Kim ES et al. Effect of arsenic trioxide on cell cycle arrest in head and neck cancer cell line PCI-1. Biochem Biophys Res Commun 1999; 265: 400-4.
26. Uslu R, Sanli UA, Sezgin C et al. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 2000; 6: 4957-64.
27. Vuky J, Yu R, Schwartz L, Motzer RJ. Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma. Invest New Drugs 2002; 20: 327-30.
28. Yacoub A, Mitchell C, Brannon J et al. MDA-7 (interleukin-24) inhibits the proliferation of renal carcinoma cells and interacts with free radicals to promote cell death and loss of reproductive capacity. Mol Cancer Ther 2003; 2: 623-32.
29. Zhang TC, Cao EH, Li JF, Ma W, Qin JF. Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer 1999; 35: 1258-63.
30. 3 on cell cycle progression and cyclins D1 and B1 expression in two glioblastoma cell lines differing in p53 status. Int J Oncol 2002; 21: 49-55.
31. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res 2002; 62: 3893-903.
32. Jing Y, Dai J, Chalmers-Redman RM, Tattoo WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102-11.
33. Yi J, Yang J, He R et al. Emodin enhances arsenic trioxide-induced apoptosis via generation of reactive oxygen species and inhibition of survival signaling. Cancer Res 2004; 64: 108-16.
34. Vaux DL, Korsmeyer SJ. Cell death in development. Cell 1999; 96: 245-54.
35. Meier P, Finch A, Evan G. Apoptosis in development. Nature 2000; 407: 796-801.
36. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-62.
37. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene 2003; 22: 8543-67.
38. Haga N, Fujita N, Tsuruo T. Mitochondrial aggregation precedes cytochrome c release from mitochondria during apoptosis. Oncogene 2003; 22: 5579-85.
39. Haga N, Naito M, Seimiya H, Tomida A, Dong J, Tsuruo T. 2-Deoxyglucose inhibits chemotherapeutic drug-induced apoptosis in human monocytic leukemia U937 cells with inhibition of c-Jun N-terminal kinase 1/stress-activated protein kinase activation. Int J Cancer 1998; 76: 86-90.
40. Tsuruo T, Naito M, Tomida A et al. Molecular targeting therapy of cancer: Drug resistance, apoptosis and survival signal. Cancer Sci 2003; 94: 15-21.
41. Huang P, Oliff A. Signaling pathways in apoptosis as potential targets for cancer therapy. Trends Cell Biol 2001; 11: 343-8.
42. Desagher S, Martinou JC. Mitochondria as the central control point of apoptosis. Trends Cell Biol 2000; 10: 369-77.
43. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6: 513-9.
44. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004; 305: 626-9.
45. Costantini P, Jacotot E, Decaudin D, Kroemer G. Mitochondrion as a novel target of anticancer chemotherapy. J Natl Cancer Inst 2000; 92: 1042-53.
46. Danial NN, Korsmeyer SJ. Cell death: Critical control points. Cell 2004; 116: 205-19.
47. Korsmeyer SJ, Wei MC, Saito M, Weiler S, Oh KJ, Schlesinger PH. Proapoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. Cell Death Differ 2000; 7: 1166-73.
48. Shaw JM, Nunnari J. Mitochondrial dynamics and division in budding yeast. Trends Cell Biol 2002; 12: 178-84.
49. Yaffe MP. Dynamic mitochondria. Nat Cell Biol 1999; 1: E149-50.
50. Bleazard W, McCaffery JM, King EJ et al. The dynamin-related GTPase Dnm1 regulates mitochondrial fission in yeast. Nat Cell Biol 1999; 1: 298-304.
51. van der Bliek AM. A mitochondrial division apparatus takes shape. J Cell Biol 2000; 151: F1-4.
52. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol 2003; 160: 189-200.
53. Sesaki H, Jensen RE. Division versus fusion. Dnm1p and Fzo1p antagonistically regulate mitochondrial shape. J Cell Biol 1999; 147: 699-706.
54. Fannjiang Y, Cheng WC, Lee SJ et al. Mitochondrial fission proteins regulate programmed cell death in yeast. Genes Dev 2004; 18: 2785-97.
55. Frank S, Gaume B, Bergmann-Leitner ES et al. The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. Dev Cell 2001; 1: 515-25.
56. Jagasia R, Grote P, Westermann B, Conradt B. DRP-1-mediated mitochondrial fragmentation during EGL-1-induced cell death in C. elegans. Nature 2005; 433: 754-60.
57. Lee YJ, Jeong SY, Karbowski M, Smith CL, Youle RJ. Roles of the mammalian mitochondrial fission and fusion mediators Fis1, Drp1, and Opa1 in apoptosis. Mol Biol Cell 2004; 15: 5001-11.
58. Oakes SA, Korsmeyer SJ. Untangling the web: Mitochondrial fission and apoptosis. Dev Cell 2004; 7: 460-2.
59. Sugioka R, Shimizu S, Tsujimoto Y. Fzo1, a protein involved in mitochondrial fusion, inhibits apoptosis. J Biol Chem 2004; 279: 52 726-34.
60. Fransson A, Ruusala A, Aspenstrom P. Atypical Rho GTPases have roles in mitochondrial homeostasis and apoptosis. J Biol Chem 2003; 278: 6495-502.
61. Sturlan S, Baumgartner M, Roth E, Bachleitner-Hofmann T. Docosahexaenoic acid enhances arsenic trioxide-mediated apoptosis in arsenic trioxide-resistant HL-60 cells. Blood 2003; 101: 4990-7.